ArticleCell reports. Medicine2021

ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors.

Ana Portelinha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.